Page contentsPage contents Key facts Decision Key facts Active substance sildenafil citratetestosterone Therapeutic area Psychiatric disorders Decision number EMA/PE/0000181891 PIP number EMA/PE/0000181891 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of hypoactive sexual desire disorder Route(s) of administration Sublingual useOral use Contact for public enquiries Freya Pharma Solutions Holding B.V.E-mail: info@freyapharmasolutions.comTel: +31 646237282 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 25/10/2024 Compliance check done No Decision EMA/PE/0000181891: EMA decision of 25 October 2024 on the granting of a product specific waiver for sildenafil citrate, testosteroneAdopted Reference Number: EMADOC-1700519818-1690068 English (EN) (180.29 KB - PDF)First published: 23/10/2025 View Share this page